Publications

Title

Author

Year

Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines.

Pelzer, PT; SEELEY, J; Sun, FY; Tameris, M; Tao, L; Yanlin, Z; Moosan, H; WEERASURIYA, C; Asaria, M; Jayawardana, S; WHITE, RG; Harris, RC;

2018

PLOS Global Public Health, (2018).2 5 10.1371/journal.pgph.0000076.

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.

CHEN, C; Cervero Liceras, F; FLASCHE, S; Sidharta, S; Yoong, J; SUNDARAM, N; JIT, M;

2018

LANCET GLOBAL HEALTH, (2018).7 1 10.1016/S2214-109X(18)30422-4.

Functional antibodies against Plasmodium falciparum sporozoites are associated with a longer time to qPCR-detected infection among schoolchildren in Burkina Faso.

Barry, A; Behet, MC; Nébié, I; Lanke, K; GRIGNARD, L; Ouedraogo, A; Soulama, I; DRAKELEY, C; Sauerwein, R; Bolscher, JM; Dechering, KJ; Bousema, T; Tiono, AB; GONÇALVES, BP;

2018

Wellcome Open Research, (2018).3, 10.12688/wellcomeopenres.14932.1.

KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization.

Kamuyu, G; Tuju, J; Kimathi, R; Mwai, K; Mburu, J; Kibinge, N; Chong Kwan, M; Hawkings, S; Yaa, R; Chepsat, E; Njunge, JM; Chege, T; Guleid, F; Rosenkranz, M; Kariuki, CK; Frank, R; Kinyanjui, SM; Murungi, LM; Bejon, P; Färnert, A; TETTEH, KK A; Beeson, JG; CONWAY, DJ; Marsh, K; Rayner, JC; ... Osier, FH A.

2018

Frontiers in Immunology, (2018).9, 10.3389/fimmu.2018.02866.

Strengthening national vaccine decision-making: Assessing the impact of SIVAC Initiative support on national immunisation technical advisory group (NITAG) functionality in 77 low and middle-income countries.

VAN ZANDVOORT, K; HOWARD, N; MOUNIER-JACK, S; JIT, M;

2018

Vaccine, (2018).37 3 10.1016/j.vaccine.2018.11.070.

BCG vaccination for bovine tuberculosis; conclusions from the Jerusalem One Health workshop.

Marais, BJ; Buddle, BM; De Klerk-Lorist, L-M; NGUIPDOP-DJOMO, P; Quinn, F; Greenblatt, C;

2018

Transboundary and emerging diseases, (2018).66 2 10.1111/tbed.13089.

Vaccination in England: a review of why business as usual is not enough to maintain coverage.

CROCKER-BUQUE, T; MOUNIER-JACK, S;

2018

BMC public health, (2018).18 1 10.1186/s12889-018-6228-5.

Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys.

Dunne, EM; Satzke, C; Ratu, FT; Neal, EF G; Boelsen, LK; Matanitobua, S; Pell, CL; Nation, ML; Ortika, BD; Reyburn, R; Jenkins, K; Nguyen, C; Gould, K; Hinds, J; Tikoduadua, L; Kado, J; Rafai, E; Kama, M; MULHOLLAND, EK; Russell, FM;

2018

LANCET GLOBAL HEALTH, (2018).6 12 10.1016/S2214-109X(18)30383-8.

Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India.

Atmakuri, K; Penn-Nicholson, A; Tanner, R; DOCKRELL, HM;

2018

TUBERCULOSIS, (2018).113, 10.1016/j.tube.2018.08.013.

An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia.

Marshall, LE; Nelson, M; Davies, CH; Whelan, AO; Jenner, DC; Moule, MG; Denman, C; CUCCUI, J; Atkins, TP; WREN, BW; Prior, JL;

2018

JOURNAL OF IMMUNOLOGY RESEARCH, (2018).2018, 10.1155/2018/8087916.